Compare Cenovus Energy Inc (CVE) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs Merck & Co., Inc. — how do they compare? Cenovus Energy Inc trades at $27.16 (market cap $50.90B), while Merck & Co., Inc. trades at $123.31 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 5.9× Cenovus Energy Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.82%). Which is the better fit depends on your goals.
| CVE | MRK | |
|---|---|---|
Market Cap | $50.90B | $298.31B |
Sector | Energy | Health |
52-Week High | $31.80 | $129.52 |
52-Week Low | $13.96 | $77.60 |
Enterprise Value | $58.77B | $341.72B |
Dividend Yield | 2.25% | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $27.61, up 4.58% with strong bullish technical indicators and consistent earnings beats. The stock shows solid fundamentals with a P/E of 15.62, ROE of 14.86%, and improving cash flow projections. Recent news highlights benefits from rising crude prices and operational synergies from MEG Energy acquisition.
CVE presents a compelling investment case with attractive valuation, strong profitability metrics, and positive analyst sentiment (40.74% buy ratings). Key risks include oil price volatility and execution challenges in growth projects. The integrated business model provides resilience across energy cycles.
Merck (MRK) trades at $123.43, down 0.48% on the day, with a bullish technical signal and strong institutional buying. Recent earnings beat expectations in three of the last four quarters, with Q2 2026 results pending. The company's acquisition of Terns Pharmaceuticals for approximately $6.7 billion aims to bolster its oncology pipeline, while solid profitability metrics include a net income margin of 13.59% and ROE of 18.97% for 2025.
The outlook remains positive with a consensus price target of $137.30, implying 11% upside. Key risks include rising debt levels and competitive pressures in the pharmaceutical sector. Analysts are predominantly bullish, with 68% recommending Buy, supported by robust cash flow and strategic M&A activity to drive long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
